{"protocolSection": {"identificationModule": {"nctId": "NCT02989649", "orgStudyIdInfo": {"id": "Alogliptin-5009"}, "organization": {"fullName": "Takeda", "class": "INDUSTRY"}, "briefTitle": "Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice", "officialTitle": "A Prospective, Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice"}, "statusModule": {"statusVerifiedDate": "2019-01", "overallStatus": "TERMINATED", "whyStopped": "Business Decision; No Safety Or Efficacy Concerns", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-12-22", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-01-26", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-01-26", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-12-08", "studyFirstSubmitQcDate": "2016-12-08", "studyFirstPostDateStruct": {"date": "2016-12-12", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2019-01-23", "resultsFirstSubmitQcDate": "2019-01-23", "resultsFirstPostDateStruct": {"date": "2019-04-19", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-01-23", "lastUpdatePostDateStruct": {"date": "2019-04-19", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Takeda", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to observe alogliptin and alogliptin fixed-dose combinations (FDCs) utilization patterns, as well as clinical response to treatment with alogliptin or alogliptin FDCs, in standard clinical practice.", "detailedDescription": "The drug being studied in this study is called alogliptin and alogliptin FDCs. Alogliptin and alogliptin FDCs is being researched to treat people who have diabetes mellitus type 2. This study will look at the glycosylated hemoglobin (HbA1c) level dynamics in participants with diabetes mellitus type 2.\n\nThe study enrolled 593 patients. Alogliptin and alogliptin FDCs will be prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study).\n\nThis multi-center study will be conducted in China. The overall duration of study for observation will be approximately 6 months, or up to loss to follow-up or death, whichever occurs first. Participants will make multiple visits to the clinic as per regular doctor's appointments."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"], "keywords": ["Drug Therapy"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 593, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Alogliptin or Alogliptin Fixed Dose Combinations (FDCs)", "description": "Participants with type 2 diabetes mellitus (T2DM) who received alogliptin or alogliptin FDCs, orally, prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study) were observed for approximately 6 months, or up to loss to follow-up or death, whichever occurred first.", "interventionNames": ["Drug: Alogliptin", "Drug: Alogliptin FDC With Pioglitazone", "Drug: Alogliptin FDC With Metformin"]}], "interventions": [{"type": "DRUG", "name": "Alogliptin", "description": "Alogliptin tablets", "armGroupLabels": ["Alogliptin or Alogliptin Fixed Dose Combinations (FDCs)"]}, {"type": "DRUG", "name": "Alogliptin FDC With Pioglitazone", "description": "Alogliptin FDC with pioglitazone tablets", "armGroupLabels": ["Alogliptin or Alogliptin Fixed Dose Combinations (FDCs)"]}, {"type": "DRUG", "name": "Alogliptin FDC With Metformin", "description": "Alogliptin FDC with metformin tablets", "armGroupLabels": ["Alogliptin or Alogliptin Fixed Dose Combinations (FDCs)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Glycosylated Hemoglobin (HbA1c) Level at Month 6", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Month 6 relative to baseline. Glycosylated hemoglobin (HbA1c) as a diagnostic criteria of diabetes mellitus is \u22656.5%. A negative change from Baseline indicates improvement.", "timeFrame": "Baseline and Month 6"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Glycosylated Hemoglobin (HbA1c) Level at Month 6 in Subgroups of Participants With Different Clinical Characteristics", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Month 6 relative to baseline. Glycosylated hemoglobin (HbA1c) as a diagnostic criteria of diabetes mellitus is \u22656.5%. Subgroups included participants with different baseline clinical characteristics with predictors such as prior therapy of diabetes mellitus, sex, age group, cardiovascular risk group, therapy type (monotherapy or combined therapy), baseline body mass index (BMI) and initial glycemic control. A negative change from Baseline indicates improvement.", "timeFrame": "Baseline and Month 6"}, {"measure": "Percentage of Participants With a Decrease in HbA1c Level by <7.0%", "description": "Percentage of participants with a decrease of \\<7.0% from baseline in HbA1c were reported.", "timeFrame": "Baseline and Month 6"}, {"measure": "Percentage of Participants With a Decrease in HbA1c Level by >0.3% and No Tolerability Findings", "description": "Percentage of participants with a decrease of \\>0.3% from baseline in HbA1c along with no tolerability findings were reported. Tolerability findings included hypoglycemic event, or weight gain \u22655%.", "timeFrame": "Baseline and Month 6"}, {"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) Level Over Time", "description": "The change between the fasting plasma glucose value collected at Months 3 and 6 relative to baseline. A negative change from Baseline indicates improvement.", "timeFrame": "Baseline and Months 3 and 6"}, {"measure": "Change From Baseline in Glycosylated Hemoglobin (HbA1c) Level Over Time", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Months 3 and 6 relative to baseline. A negative change from Baseline indicates improvement.", "timeFrame": "Baseline and Months 3 and 6"}, {"measure": "Number of Participants With Adverse Drug Reactions (ADRs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)", "description": "An ADR is defined as any response to a medicinal product that is noxious and unintended and that occurs at doses normally used in humans for the prophylaxis, diagnosis, or therapy of diseases or for the restoration, correction, or modification of physiological function. An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria. Adverse events such as pancreatitis, hepatic disorders, and hypersensitivity reactions (including angioedema, anaphylaxis, and Stevens-Johnson syndrome) were considered as AESI.", "timeFrame": "Baseline up to Month 6"}, {"measure": "Percentage of Participants Who Remain on Treatment With Alogliptin or Alogliptin FDCs", "timeFrame": "Months 3 and 6"}, {"measure": "Time to Alogliptin or Alogliptin FDCs Dose Escalation or Dose Reduction", "timeFrame": "Months 3 and 6"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Has a diagnosis of T2DM.\n2. Has made the decision, along with his/her treating physician, to begin treatment with alogliptin or alogliptin fixed-dose combinations (FDCs).\n3. Has an glycated hemoglobin (HbA1c) value recorded at most 3 months before initiation of treatment with alogliptin or alogliptin FDCs.\n4. Alogliptin or alogliptin FDCs is prescribed according to the approved label for China and Hong Kong.\n\nExclusion Criteria:\n\n1. Has gestational diabetes or type 1 diabetes mellitus.\n2. Has used Dipeptidyl peptidase-4 inhibitors (DPP-IV inhibitors) or Glucagon like peptide-1 agonists (aGLP-1) within the 3 months prior to the start of alogliptin or alogliptin FDCs treatment.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "Adult participants diagnosed with type 2 diabetes mellitus (T2DM) will be observed.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director Clinical Science", "affiliation": "Takeda", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "Beijing", "state": "Beijing", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"city": "Wuhan", "state": "Hubei", "country": "China", "geoPoint": {"lat": 30.58333, "lon": 114.26667}}, {"city": "Dalian", "state": "Liaoning", "country": "China", "geoPoint": {"lat": 38.91222, "lon": 121.60222}}, {"city": "Shenyang", "state": "Liaoning", "country": "China", "geoPoint": {"lat": 41.79222, "lon": 123.43278}}, {"city": "Jinan", "state": "Shandong", "country": "China", "geoPoint": {"lat": 36.66833, "lon": 116.99722}}, {"city": "Qingdao", "state": "Shandong", "country": "China", "geoPoint": {"lat": 36.06488, "lon": 120.38042}}, {"city": "Tai'an", "state": "Shandong", "country": "China", "geoPoint": {"lat": 36.18528, "lon": 117.12}}, {"city": "Taian", "state": "Shandong", "country": "China", "geoPoint": {"lat": 36.18528, "lon": 117.12}}, {"city": "Tianjin", "state": "Tianjin", "country": "China", "geoPoint": {"lat": 39.14222, "lon": 117.17667}}, {"city": "Sai Ying Pun", "country": "Hong Kong", "geoPoint": {"lat": 22.28998, "lon": 114.14223}}, {"city": "Sha Tin", "country": "Hong Kong", "geoPoint": {"lat": 22.38333, "lon": 114.18333}}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants with a diagnosis of Type 2 Diabetes Mellitus (T2DM) prescribed alogliptin or alogliptin Fixed Dose Combinations (FDCs) with either metformin or pioglitazone were enrolled in this observational study.", "recruitmentDetails": "Participants took part in the study at 16 investigative sites in China from 22 Dec 2016 to 26 Jan 2018.", "groups": [{"id": "FG000", "title": "Alogliptin or Alogliptin Fixed Dose Combinations (FDCs)", "description": "Participants with type 2 diabetes mellitus (T2DM) who received alogliptin or alogliptin FDCs, orally, prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study) were observed for approximately 6 months, or up to loss to follow-up or death, whichever occurred first."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "593"}]}, {"type": "Started But Not Treated", "achievements": [{"groupId": "FG000", "numSubjects": "84"}]}, {"type": "Eligible to Enter Into Treatment Period", "achievements": [{"groupId": "FG000", "numSubjects": "509"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "173"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "420"}]}], "dropWithdraws": [{"type": "Patient/Investigator's Decision to Stop", "reasons": [{"groupId": "FG000", "numSubjects": "403"}]}, {"type": "Adverse Event/Adverse Drug Reaction", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Lost For Observation During Study", "reasons": [{"groupId": "FG000", "numSubjects": "3"}]}, {"type": "Reason Not Specified", "reasons": [{"groupId": "FG000", "numSubjects": "13"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All participants dosed included participants with complete demographic information and eligible for the study and dosed at least once.", "groups": [{"id": "BG000", "title": "Alogliptin or Alogliptin Fixed Dose Combinations (FDCs)", "description": "Participants with type 2 diabetes mellitus (T2DM) who received alogliptin or alogliptin FDCs, orally, prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study) were observed for approximately 6 months, or up to loss to follow-up or death, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "509"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "509"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "55.3", "spread": "12.65"}]}]}]}, {"title": "Age, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "509"}]}], "categories": [{"title": "<45 years", "measurements": [{"groupId": "BG000", "value": "92"}]}, {"title": ">=45 to <65 years", "measurements": [{"groupId": "BG000", "value": "309"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "108"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "509"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "207"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "302"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "509"}]}], "categories": [{"title": "Asian", "measurements": [{"groupId": "BG000", "value": "508"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "1"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "509"}]}], "categories": [{"title": "Han Nationality", "measurements": [{"groupId": "BG000", "value": "504"}]}, {"title": "Other", "measurements": [{"groupId": "BG000", "value": "5"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "China", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "509"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "509"}]}]}]}, {"title": "Height", "populationDescription": "Number analyzed is the number of participants with evaluable data for this baseline measure.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "500"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "167.37", "spread": "8.089"}]}]}]}, {"title": "Weight", "populationDescription": "Number analyzed is the number of participants with evaluable data for this baseline measure.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "500"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "72.66", "spread": "12.208"}]}]}]}, {"title": "Body Mass Index (BMI)", "description": "Body Mass Index(BMI)=weight (kg)/\\[height (m)\\^2\\]. BMI is calculated using the participant's baseline height and weight measurement.", "populationDescription": "Number analyzed is the number of participants with evaluable data for this baseline measure.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "500"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "25.86", "spread": "3.500"}]}]}]}, {"title": "Body Mass Index, Customized", "description": "Body Mass Index(BMI)=weight (kg)/\\[height (m)\\^2\\]. BMI is calculated using the participant's baseline height and weight measurement.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "509"}]}], "categories": [{"title": "<25 kg/m^2", "measurements": [{"groupId": "BG000", "value": "193"}]}, {"title": "25 to <30 kg/m^2", "measurements": [{"groupId": "BG000", "value": "256"}]}, {"title": ">=30 kg/m^2", "measurements": [{"groupId": "BG000", "value": "51"}]}, {"title": "Missing", "measurements": [{"groupId": "BG000", "value": "9"}]}]}]}, {"title": "Glycosylated hemoglobin (HbA1c) Level", "description": "Glycosylated hemoglobin is the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound. Glycosylated hemoglobin as a diagnostic criteria of diabetes mellitus is \u22656.5%.", "populationDescription": "Number analyzed is the number of participants with evaluable data for this baseline measure.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of glycosylated hemoglobin", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "498"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "8.690", "spread": "1.8807"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Glycosylated Hemoglobin (HbA1c) Level at Month 6", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Month 6 relative to baseline. Glycosylated hemoglobin (HbA1c) as a diagnostic criteria of diabetes mellitus is \u22656.5%. A negative change from Baseline indicates improvement.", "populationDescription": "All participants dosed included participants with complete demographic information and eligible for the study and dosed at least once. Overall number of participants analyzed is the number of participants with evaluable data at the given time-point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of glycosylated hemoglobin", "timeFrame": "Baseline and Month 6", "groups": [{"id": "OG000", "title": "Alogliptin or Alogliptin Fixed Dose Combinations (FDCs)", "description": "Participants with type 2 diabetes mellitus (T2DM) who received alogliptin or alogliptin FDCs, orally, prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study) were observed for approximately 6 months, or up to loss to follow-up or death, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "140"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.092", "spread": "1.6803"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Statistical analysis for data at Baseline compared to the data at Month 6", "nonInferiorityType": "OTHER", "pValue": "<0.001", "statisticalMethod": "Regression, Linear", "paramType": "Least Square Mean (LSM)", "paramValue": "-1.25", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.44", "ciUpperLimit": "-1.05", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.098", "estimateComment": "The LSM and CI are from Mixed effect Model Repeat Measurement (MMRM) model, that used visit as a predictor and baseline value as a covariate. For change from baseline, covariance structure=Unstructured."}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glycosylated Hemoglobin (HbA1c) Level at Month 6 in Subgroups of Participants With Different Clinical Characteristics", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Month 6 relative to baseline. Glycosylated hemoglobin (HbA1c) as a diagnostic criteria of diabetes mellitus is \u22656.5%. Subgroups included participants with different baseline clinical characteristics with predictors such as prior therapy of diabetes mellitus, sex, age group, cardiovascular risk group, therapy type (monotherapy or combined therapy), baseline body mass index (BMI) and initial glycemic control. A negative change from Baseline indicates improvement.", "populationDescription": "All participants dosed included participants with complete demographic information and eligible for the study and dosed at least once. Overall number of participants analyzed is the number of participants with evaluable data at the given time-point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of glycosylated hemoglobin", "timeFrame": "Baseline and Month 6", "groups": [{"id": "OG000", "title": "Alogliptin or Alogliptin Fixed Dose Combinations (FDCs)", "description": "Participants with type 2 diabetes mellitus (T2DM) who received alogliptin or alogliptin FDCs, orally, prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study) were observed for approximately 6 months, or up to loss to follow-up or death, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "140"}]}], "classes": [{"title": "Prior Therapy of Diabetes Mellitus, Ever Used", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.154", "spread": "1.7555"}]}]}, {"title": "Prior Therapy of Diabetes Mellitus, Never Used", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.882", "spread": "1.4015"}]}]}, {"title": "Sex, Male", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "86"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.055", "spread": "1.5898"}]}]}, {"title": "Sex, Female", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.150", "spread": "1.8292"}]}]}, {"title": "Age, <45 years", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.658", "spread": "1.8206"}]}]}, {"title": "Age, >=45 to <65 years", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "78"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.370", "spread": "1.7121"}]}]}, {"title": "Age,>=65 years", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.203", "spread": "1.1423"}]}]}, {"title": "Cardiovascular Risk Group, Yes", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.100", "spread": "2.4973"}]}]}, {"title": "Cardiovascular Risk Group, No", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "133"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.092", "spread": "1.6400"}]}]}, {"title": "Therapy Type, Monotherapy", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.032", "spread": "1.5122"}]}]}, {"title": "Therapy Type, Combined Therapy", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "114"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.106", "spread": "1.7222"}]}]}, {"title": "Baseline BMI, <25 kg/m^2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.101", "spread": "1.7339"}]}]}, {"title": "Baseline BMI, 25 to <30 kg/m^2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.037", "spread": "1.6151"}]}]}, {"title": "Baseline BMI, >=30 kg/m^2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.342", "spread": "1.8530"}]}]}, {"title": "Initial Glycemic Control, <7%", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.046", "spread": "0.7345"}]}]}, {"title": "Initial Glycemic Control, >=7%", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "99"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.525", "spread": "1.7713"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Statistical analysis for subgroup: Prior therapy of diabetes mellitus, Ever used or Never used", "nonInferiorityType": "OTHER", "pValue": "0.423", "statisticalMethod": "Regression, Linear"}, {"groupIds": ["OG000"], "groupDescription": "Statistical analysis for subgroup: Sex, Male or Female", "nonInferiorityType": "OTHER", "pValue": "0.747", "statisticalMethod": "Regression, Linear"}, {"groupIds": ["OG000"], "groupDescription": "Statistical analysis for subgroup: Age, \\<45 or \\>=45 to \\<65 years or \\>=65 years", "nonInferiorityType": "OTHER", "pValue": "<0.001", "statisticalMethod": "Regression, Linear"}, {"groupIds": ["OG000"], "groupDescription": "Statistical analysis for subgroup: Cardiovascular risk group, Yes or No", "nonInferiorityType": "OTHER", "pValue": "0.990", "statisticalMethod": "Regression, Linear"}, {"groupIds": ["OG000"], "groupDescription": "Statistical analysis for subgroup: Therapy type, Monotherapy or Combined therapy", "nonInferiorityType": "OTHER", "pValue": "0.841", "statisticalMethod": "Regression, Linear"}, {"groupIds": ["OG000"], "groupDescription": "Statistical analysis for subgroup: Baseline BMI, \\<25 or 25 to \\<30 or \\>=30 kg/m\\^2", "nonInferiorityType": "OTHER", "pValue": "0.847", "statisticalMethod": "Regression, Linear"}, {"groupIds": ["OG000"], "groupDescription": "Statistical analysis for subgroup: Initial glycemic control, \\<7% or \\>=7%", "nonInferiorityType": "OTHER", "pValue": "<0.001", "statisticalMethod": "Regression, Linear"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With a Decrease in HbA1c Level by <7.0%", "description": "Percentage of participants with a decrease of \\<7.0% from baseline in HbA1c were reported.", "populationDescription": "All participants dosed included participants with complete demographic information and eligible for the study and dosed at least once. Overall number of participants analyzed is the number of participants with evaluable data at the given time-point.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline and Month 6", "groups": [{"id": "OG000", "title": "Alogliptin or Alogliptin Fixed Dose Combinations (FDCs)", "description": "Participants with type 2 diabetes mellitus (T2DM) who received alogliptin or alogliptin FDCs, orally, prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study) were observed for approximately 6 months, or up to loss to follow-up or death, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "147"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "51.0", "lowerLimit": "0.43", "upperLimit": "0.59"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With a Decrease in HbA1c Level by >0.3% and No Tolerability Findings", "description": "Percentage of participants with a decrease of \\>0.3% from baseline in HbA1c along with no tolerability findings were reported. Tolerability findings included hypoglycemic event, or weight gain \u22655%.", "populationDescription": "All participants dosed included participants with complete demographic information and eligible for the study and dosed at least once. Overall number of participants analyzed is the number of participants with evaluable data at the given time-point.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline and Month 6", "groups": [{"id": "OG000", "title": "Alogliptin or Alogliptin Fixed Dose Combinations (FDCs)", "description": "Participants with type 2 diabetes mellitus (T2DM) who received alogliptin or alogliptin FDCs, orally, prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study) were observed for approximately 6 months, or up to loss to follow-up or death, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "140"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "64.3", "lowerLimit": "0.56", "upperLimit": "0.72"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) Level Over Time", "description": "The change between the fasting plasma glucose value collected at Months 3 and 6 relative to baseline. A negative change from Baseline indicates improvement.", "populationDescription": "All participants dosed included participants with complete demographic information and eligible for the study and dosed at least once. Number analyzed is the number of participants with evaluable data at the given time-point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Months 3 and 6", "groups": [{"id": "OG000", "title": "Alogliptin or Alogliptin Fixed Dose Combinations (FDCs)", "description": "Participants with type 2 diabetes mellitus (T2DM) who received alogliptin or alogliptin FDCs, orally, prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study) were observed for approximately 6 months, or up to loss to follow-up or death, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "509"}]}], "classes": [{"title": "Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "213"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.058", "spread": "3.0026"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "82"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.714", "spread": "2.9802"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Statistical analysis for data at Baseline compared to the data at Month 3", "nonInferiorityType": "OTHER", "paramType": "Least Square Mean (LSM)", "paramValue": "-0.95", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.29", "ciUpperLimit": "-0.62", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.170", "estimateComment": "The LSM and CI are from Mixed effect Model Repeat Measurement (MMRM) model, that used visit as a predictor and baseline value as a covariate. For change from baseline, covariance structure=Unstructured."}, {"groupIds": ["OG000"], "groupDescription": "Statistical analysis for data at Baseline compared to the data at Month 6", "nonInferiorityType": "OTHER", "paramType": "Least Square Mean (LSM)", "paramValue": "-0.87", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.36", "ciUpperLimit": "-0.39", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.245", "estimateComment": "The LSM and CI are from Mixed effect Model Repeat Measurement (MMRM) model, that used visit as a predictor and baseline value as a covariate. For change from baseline, covariance structure=Unstructured."}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glycosylated Hemoglobin (HbA1c) Level Over Time", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Months 3 and 6 relative to baseline. A negative change from Baseline indicates improvement.", "populationDescription": "All participants dosed included participants with complete demographic information and eligible for the study and dosed at least once. Number analyzed is the number of participants with evaluable data at the given time-point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of glycosylated hemoglobin", "timeFrame": "Baseline and Months 3 and 6", "groups": [{"id": "OG000", "title": "Alogliptin or Alogliptin Fixed Dose Combinations (FDCs)", "description": "Participants with type 2 diabetes mellitus (T2DM) who received alogliptin or alogliptin FDCs, orally, prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study) were observed for approximately 6 months, or up to loss to follow-up or death, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "509"}]}], "classes": [{"title": "Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "332"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.022", "spread": "2.3669"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "140"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.092", "spread": "1.6803"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Statistical analysis for data at Baseline compared to the data at Month 3", "nonInferiorityType": "OTHER", "paramType": "Least Square Mean (LSM)", "paramValue": "-0.95", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.18", "ciUpperLimit": "-0.72", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.117", "estimateComment": "The LSM and CI are from Mixed effect Model Repeat Measurement (MMRM) model, that used visit as a predictor and baseline value as a covariate. For change from baseline, covariance structure=Unstructured."}, {"groupIds": ["OG000"], "groupDescription": "Statistical analysis for data at Baseline compared to the data at Month 6", "nonInferiorityType": "OTHER", "paramType": "Least Square Mean", "paramValue": "-1.25", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.44", "ciUpperLimit": "-1.05", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.098", "estimateComment": "The LSM and CI are from Mixed effect Model Repeat Measurement (MMRM) model, that used visit as a predictor and baseline value as a covariate. For change from baseline, covariance structure=Unstructured."}]}, {"type": "SECONDARY", "title": "Number of Participants With Adverse Drug Reactions (ADRs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)", "description": "An ADR is defined as any response to a medicinal product that is noxious and unintended and that occurs at doses normally used in humans for the prophylaxis, diagnosis, or therapy of diseases or for the restoration, correction, or modification of physiological function. An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria. Adverse events such as pancreatitis, hepatic disorders, and hypersensitivity reactions (including angioedema, anaphylaxis, and Stevens-Johnson syndrome) were considered as AESI.", "populationDescription": "All participants dosed included participants with complete demographic information and eligible for the study and dosed at least once.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline up to Month 6", "groups": [{"id": "OG000", "title": "Alogliptin or Alogliptin Fixed Dose Combinations (FDCs)", "description": "Participants with type 2 diabetes mellitus (T2DM) who received alogliptin or alogliptin FDCs, orally, prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study) were observed for approximately 6 months, or up to loss to follow-up or death, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "509"}]}], "classes": [{"title": "Adverse Drug Reaction (ADR)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Serious Adverse Event (SAE)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Adverse Event of Special Interest (AESI)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who Remain on Treatment With Alogliptin or Alogliptin FDCs", "populationDescription": "All participants dosed included participants with complete demographic information and eligible for the study and dosed at least once. Number analyzed is the number of participants with evaluable data at the given time-point.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Months 3 and 6", "groups": [{"id": "OG000", "title": "Alogliptin or Alogliptin Fixed Dose Combinations (FDCs)", "description": "Participants with type 2 diabetes mellitus (T2DM) who received alogliptin or alogliptin FDCs, orally, prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study) were observed for approximately 6 months, or up to loss to follow-up or death, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "509"}]}], "classes": [{"title": "Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "380"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "100"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "154"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "100"}]}]}]}, {"type": "SECONDARY", "title": "Time to Alogliptin or Alogliptin FDCs Dose Escalation or Dose Reduction", "populationDescription": "No participant was experienced the dose adjustment (dose escalation or dose reduction).", "reportingStatus": "POSTED", "timeFrame": "Months 3 and 6", "groups": [{"id": "OG000", "title": "Alogliptin or Alogliptin Fixed Dose Combinations (FDCs)", "description": "Participants with type 2 diabetes mellitus (T2DM) who received alogliptin or alogliptin FDCs, orally, prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study) were observed for approximately 6 months, or up to loss to follow-up or death, whichever occurred first."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Up to Month 6", "description": "At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.", "eventGroups": [{"id": "EG000", "title": "Alogliptin or Alogliptin Fixed Dose Combinations (FDCs)", "description": "Participants with type 2 diabetes mellitus (T2DM) who received alogliptin or alogliptin FDCs, orally, prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study) were observed for approximately 6 months, or up to loss to follow-up or death, whichever occurred first.", "deathsNumAffected": 0, "deathsNumAtRisk": 509, "seriousNumAffected": 0, "seriousNumAtRisk": 509, "otherNumAffected": 55, "otherNumAtRisk": 509}], "otherEvents": [{"term": "Abdominal discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 48, "numAtRisk": 509}]}, {"term": "Hypertriglyceridaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA version 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 509}]}, {"term": "Dyslipidaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA version 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 509}]}, {"term": "Hyperuricaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA version 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 509}]}, {"term": "Hepatic function abnormal", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA version 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 509}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA version 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 509}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 509}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property."}, "pointOfContact": {"title": "Medical Director", "organization": "Takeda", "email": "trialdisclosures@takeda.com", "phone": "+1-877-825-3327"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2016-04-01", "uploadDate": "2019-01-23T10:26", "filename": "Prot_000.pdf", "size": 1358446}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2018-03-12", "uploadDate": "2019-01-23T10:26", "filename": "SAP_001.pdf", "size": 1052141}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000077205", "term": "Pioglitazone"}, {"id": "C000520853", "term": "Alogliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M1693", "name": "Pioglitazone", "asFound": "Registry", "relevance": "HIGH"}, {"id": "M247106", "name": "Alogliptin", "asFound": "Reflex", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}